Universal Ibogaine Inc. (TSXV:IBO)

Market Cap	7.82M
Revenue (ttm)	2.06M
Net Income (ttm)	-1.48M
Shares Out	312.86M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,010
Average Volume	234,738
Open	0.0250
Previous Close	0.0250
Day's Range	0.0250 - 0.0250
52-Week Range	0.0050 - 0.0450
Beta	6.47
RSI	48.22
Earnings Date	Nov 28, 2025

About Universal Ibogaine

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Karos
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: IBO

Financial Performance

In 2024, Universal Ibogaine's revenue was 2.33 million, an increase of 126.32% compared to the previous year's 1.03 million. Losses were -2.05 million, -14.17% less than in 2023.